Welcome to our dedicated page for Cyclerion Therapeutics news (Ticker: CYCN), a resource for investors and traders seeking the latest updates and insights on Cyclerion Therapeutics stock.
Cyclerion Therapeutics, Inc. (CYCN) is a Nasdaq-listed clinical-stage biopharmaceutical company that provides frequent updates on its progress in neuropsychiatric drug development and the monetization of its legacy soluble guanylate cyclase (sGC) portfolio. This news page aggregates company press releases and market-moving announcements so readers can follow how Cyclerion’s strategy and pipeline evolve over time.
Recent news highlights Cyclerion’s transformation into a neuropsychiatric company, centered on an individualized therapy for treatment-resistant depression (TRD). The company has reported a license agreement with the Massachusetts Institute of Technology for technology to treat neuropsychiatric disorders and has announced CYC-126, an anesthetic-based investigational therapy that uses real-time EEG monitoring and algorithm-guided dosing, as its lead program for TRD.
Investors and observers can also track Cyclerion’s collaboration and business development activity. Updates include an application-specific, exclusive collaboration with Medsteer SAS to integrate closed-loop anesthetic delivery technology into CYC-126, as well as agreements to sell or license legacy sGC assets such as zagociguat, CY3018, praliciguat, and olinciguat. These items illustrate how the company aims to generate non-dilutive funding while building its neuropsychiatric pipeline.
In addition, the news flow covers corporate governance and capital markets developments, including board appointments, leadership changes, reverse stock split actions, and Nasdaq listing compliance updates. By reviewing this page regularly, readers can follow Cyclerion’s clinical plans, partnership announcements, licensing milestones, and strategic updates that may influence the CYCN stock narrative.
Cyclerion (Nasdaq: CYCN) announced an exclusive, application-specific collaboration with Medsteer to integrate Medsteer’s validated EEG-guided closed-loop anesthetic delivery technology into Cyclerion’s lead program, CYC-126, a precision anesthetic-based investigational therapy for treatment-resistant depression. Cyclerion expects to complete device integration and finalize its proprietary drug delivery system ahead of a planned multinational Phase 2 POC study in the second half of 2026, with initial POC data currently expected in 2027. The company plans to seek first patient enrollment in Australia in 2026 via the CTN/HREC pathway.
Medsteer’s dataset spans 9,000+ patients across 25+ clinical settings; the collaboration includes an option-to-license and leverages primarily FDA-cleared components.
Cyclerion Therapeutics (CYCN) announced a strategic relaunch as a neuropsychiatric company through a licensing agreement with MIT. The company's transformation focuses on developing novel therapies for neuropsychiatric conditions, starting with treatment-resistant depression (TRD).
The company's lead program combines anesthetic agents with a proprietary tech-driven system to resynchronize brain region communication for 3 million Americans affected by TRD. A Phase 2 proof-of-concept trial is planned to begin in 2026, with initial data expected in 2027.
Under CEO Regina Graul's leadership and guided by industry experts including Dr. Errol DeSouza and Dr. Steven Hyman, Cyclerion aims to expand beyond TRD to develop additional neuropsychiatric therapies. The company will host a webcast on September 24, 2025 to discuss future plans.
Cyclerion Therapeutics (CYCN) announced key updates on monetizing its sGC stimulator portfolio. The company renegotiated its praliciguat license agreement with Akebia, securing $1.75 million in upfront and near-term payments, plus potential future milestone payments up to $560 million and tiered sales royalties from mid-single-digits to 20%.
Additionally, CYCN entered an exclusive license option agreement for olinciguat with a CVCO Therapeutics-controlled entity. This follows the May 2023 sale of CNS assets zagociguat and CY3018 to Tisento Therapeutics for $8 million and 10% equity stake.
These agreements represent the final steps in monetizing Cyclerion's historical portfolio, enabling the company to focus on acquiring new CNS assets without near-term dilution.
Cyclerion Therapeutics (Nasdaq: CYCN) has promoted Regina Graul, Ph.D., to Chief Executive Officer, President, and Board member. Since joining in December 2023, Dr. Graul has focused on reducing operating costs and leading a search and evaluation team to assess multiple business development prospects. The company's Board of Directors expressed confidence in her ability to drive growth and success.
Dr. Graul emphasized her commitment to continuing Cyclerion's evolution, highlighting the formation of a top-notch diligence team currently evaluating promising assets. She acknowledged the challenges ahead but expressed confidence in the company's potential to unlock value for patients and shareholders.
FAQ
What is the current stock price of Cyclerion Therapeutics (CYCN)?
What is the market cap of Cyclerion Therapeutics (CYCN)?
